Pentasa is a brand name for the medication known as mesalazine, also referred to as mesalamine. It is an oral prescription drug used in the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis and Crohn's disease, which are chronic inflammatory disorders affecting the digestive tract.
The pharmacological action of Pentasa involves reducing inflammation in the colon and rectum. Mesalazine functions as an aminosalicylate, exhibiting anti-inflammatory properties that help in alleviating symptoms such as abdominal pain, diarrhea, rectal bleeding, and intestinal ulcers associated with IBD.
The medicine is available in different formulations, including extended-release capsules, delayed-release tablets, and granules. These various forms allow targeted delivery of the active ingredient to different sections of the gastrointestinal tract affected by inflammation.
Pentasa is generally well-tolerated, and most common adverse effects include headache, diarrhea, nausea, abdominal pain, and flatulence. Serious side effects are rare but may include allergic reactions, pancreatitis, and changes in kidney function.
As with any medication, it is crucial to follow the prescribed dosage and instructions provided by the healthcare professional. Pentasa should not be used in patients with known hypersensitivity to salicylates or mesalazine, or those with severe liver or kidney problems.
It is essential to consult a medical professional for a complete understanding of the benefits, risks, and potential interactions of Pentasa before initiating or altering the treatment course.
